menu
    • menu

    Company profile for CatalYm

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    CatalYm is developing innovative immunotherapies targeting Growth Differentiation Factor 15 (GDF-15) to transform the tumor microenvironment and to substantially improve treatment options for patients with cancer. By making tumors accessible and susceptible again for the patient‘s own immune system CatalYm has developed its approach to overcome major limitations of existing immunotherapies and to improve cancer patient survi...
    CatalYm is developing innovative immunotherapies targeting Growth Differentiation Factor 15 (GDF-15) to transform the tumor microenvironment and to substantially improve treatment options for patients with cancer. By making tumors accessible and susceptible again for the patient‘s own immune system CatalYm has developed its approach to overcome major limitations of existing immunotherapies and to improve cancer patient survival and quality of life. CatalYm is led by an experienced management team of serial biotechnology entrepreneurs and backed by international venture capital investors.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CatalYmGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Am Klopferspitz 19 82152 Martinsried, Planegg
    Telephone
    Telephone
    +49 (0)89 2000 664 40
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.catalym.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/catalym
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CatalYm Names Christian S. Schade Chairman Of Board
    CatalYm Names Christian S. Schade Chairman Of Board

    28 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-28/catalym-appoints-christian-s-schade-as-chairman-of-the-board-of-directors

    PHARMIWEB
    28 Apr 2026
    Share Share
    Catalym Initiates Phase 2B Trial For Visugromab Combo
    Catalym Initiates Phase 2B Trial For Visugromab Combo

    02 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251202393269/en/CatalYm-Announces-First-Patient-Dosed-in-Phase-2b-Trial-Evaluating-Visugromab-in-Combination-with-Chemoimmunotherapy-as-Second-Line-Treatment-in-Metastatic-Non-squamous-NSCLC

    BUSINESSWIRE
    02 Dec 2025
    Share Share
    CatalYm Ph1/2a Data Shows Durable Visugromab Responses at ESMO
    CatalYm Ph1/2a Data Shows Durable Visugromab Responses at ESMO

    20 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251020679539/en/CatalYm-Presents-Long-Term-Phase-12a-Data-Confirming-Sustained-Responses-with-Visugromab-in-CPI-Refractory-Tumors-at-ESMO-2025

    BUSINESSWIRE
    20 Oct 2025
    Share Share
    CatalYm’s Visugromab Combo Shows Strong Ph2 Bladder Results
    CatalYm’s Visugromab Combo Shows Strong Ph2 Bladder Results

    17 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251017483380/en/CatalYm-Presents-Phase-2-Data-in-Neoadjuvant-Bladder-Cancer-Demonstrating-Substantial-Increase-of-Anti-Tumor-Activity-for-Visugromab-in-Combination-with-PD-1-Inhibitor-at-ESMO

    BUSINESSWIRE
    17 Oct 2025
    Share Share
    Catalym Initiates Phase 2b Trial For Visugromab Combo
    Catalym Initiates Phase 2b Trial For Visugromab Combo

    30 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250930495985/en/CatalYm-Announces-First-Patient-Dosed-in-Phase-2b-Trial-Evaluating-Visugromab-in-Combination-with-Chemoimmunotherapy-as-First-Line-Treatment-in-Metastatic-Non-squamous-NSCLC

    BUSINESSWIRE
    30 Sep 2025
    Share Share
    CatalYm Reports Ph 2 Bladder Cancer Trial Results at ESMO
    CatalYm Reports Ph 2 Bladder Cancer Trial Results at ESMO

    22 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250922505063/en/CatalYm-to-Present-Primary-Results-From-Phase-2-Neoadjuvant-Bladder-Cancer-Trial-in-Late-breaking-Oral-Presentation-at-ESMO

    BUSINESSWIRE
    22 Sep 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search